

# Robert Kralovics

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5744764/publications.pdf>

Version: 2024-02-01

139  
papers

15,470  
citations

34016

52  
h-index

17546

121  
g-index

144  
all docs

144  
docs citations

144  
times ranked

14091  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. <i>New England Journal of Medicine</i> , 2005, 352, 1779-1790.	13.9	3,240
2	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2013, 369, 2379-2390.	13.9	1,698
3	A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. <i>American Journal of Human Genetics</i> , 2011, 89, 168-175.	2.6	757
4	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. <i>Blood</i> , 2014, 123, 2220-2228.	0.6	522
5	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. <i>Blood</i> , 2014, 123, 1544-1551.	0.6	507
6	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood</i> , 2017, 129, 667-679.	0.6	444
7	A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. <i>Nature Genetics</i> , 2009, 41, 450-454.	9.4	352
8	Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. <i>Blood</i> , 2013, 121, 1720-1728.	0.6	281
9	Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. <i>Experimental Hematology</i> , 2002, 30, 229-236.	0.2	279
10	Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. <i>Blood</i> , 2008, 111, 1686-1689.	0.6	264
11	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. <i>Blood</i> , 2016, 127, 1325-1335.	0.6	261
12	Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. <i>Blood</i> , 2006, 108, 1377-1380.	0.6	252
13	Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine. <i>Journal of Innate Immunity</i> , 2016, 8, 111-120.	1.8	249
14	The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2006, 108, 1865-1867.	0.6	245
15	Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. <i>Genome Research</i> , 2014, 24, 2059-2065.	2.4	238
16	Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. <i>Blood</i> , 2016, 127, 325-332.	0.6	228
17	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. <i>Blood</i> , 2016, 127, 1317-1324.	0.6	220
18	p53 Lesions in Leukemic Transformation. <i>New England Journal of Medicine</i> , 2011, 364, 488-490.	13.9	202

#	ARTICLE	IF	CITATIONS
19	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Haematology,the, 2020, 7, e196-e208.	2.2	199
20	From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood, 2014, 123, 3714-3719.	0.6	174
21	Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 2005, 106, 3374-3376.	0.6	166
22	The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nature Chemical Biology, 2014, 10, 768-773.	3.9	157
23	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	0.6	153
24	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	5.8	145
25	Ropeginterferon alfa-2b, a novel IFNÎ±-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood, 2015, 126, 1762-1769.	0.6	142
26	LZTR1 is a regulator of RAS ubiquitination and signaling. Science, 2018, 362, 1171-1177.	6.0	142
27	Development of a Novel Trans-Lentiviral Vector That Affords Predictable Safety. Molecular Therapy, 2000, 2, 47-55.	3.7	139
28	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood, 2018, 132, 694-706.	0.6	132
29	Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood, 2003, 102, 1869-1871.	0.6	131
30	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology,the, 2017, 4, e595-e606.	2.2	130
31	Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humans. Genome Biology, 2016, 17, 14.	3.8	129
32	Endemic Polycythemia in Russia: Mutation in the VHL Gene. Blood Cells, Molecules, and Diseases, 2002, 28, 57-62.	0.6	121
33	Two New EPO Receptor Mutations: Truncated EPO Receptors Are Most Frequently Associated With Primary Familial and Congenital Polycythemias. Blood, 1997, 90, 2057-2061.	0.6	116
34	Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood, 2003, 102, 3793-3796.	0.6	116
35	Functional Dissection of the TBK1 Molecular Network. PLoS ONE, 2011, 6, e23971.	1.1	110
36	Frequent deletions of <i>JARID2</i> in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	2.0	107

#	ARTICLE	IF	CITATIONS
37	Loss of <i>Ezh2</i> synergizes with <i>JAK2</i> -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. <i>Journal of Experimental Medicine</i> , 2016, 213, 1479-1496.	4.2	101
38	Clonal heterogeneity in polycythemia vera patients with <i>JAK2</i> exon12 and <i>JAK2</i> -V617F mutations. <i>Blood</i> , 2008, 111, 3863-3866.	0.6	99
39	An RNA-Seq Strategy to Detect the Complete Coding and Non-Coding Transcriptome Including Full-Length Imprinted Macro ncRNAs. <i>PLoS ONE</i> , 2011, 6, e27288.	1.1	97
40	A reversible gene trap collection empowers haploid genetics in human cells. <i>Nature Methods</i> , 2013, 10, 965-971.	9.0	90
41	Chromothripsis in acute myeloid leukemia: biological features and impact on survival. <i>Leukemia</i> , 2018, 32, 1609-1620.	3.3	80
42	Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. <i>Blood</i> , 2019, 133, 2669-2681.	0.6	74
43	Germ-line <i>JAK2</i> mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to <i>JAK2</i> and HSP90 inhibitors. <i>Blood</i> , 2014, 123, 1372-1383.	0.6	69
44	The role of the <i>JAK2</i> GGCC haplotype and the <i>TET2</i> gene in familial myeloproliferative neoplasms. <i>Haematologica</i> , 2011, 96, 367-374.	1.7	67
45	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 1010-1016.	2.0	67
46	<i>CALR</i> exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. <i>Blood</i> , 2014, 123, 2416-2419.	0.6	66
47	Clonal analysis of deletions on chromosome 20q and <i>JAK2</i> -V617F in MPD suggests that <i>del20q</i> acts independently and is not one of the predisposing mutations for <i>JAK2</i> -V617F. <i>Blood</i> , 2009, 113, 2022-2027.	0.6	64
48	Genetic heterogeneity of primary familial and congenital polycythemia. <i>American Journal of Hematology</i> , 2001, 68, 115-121.	2.0	62
49	<i>MTHFD1</i> interaction with <i>BRD4</i> links folate metabolism to transcriptional regulation. <i>Nature Genetics</i> , 2019, 51, 990-998.	9.4	61
50	Genetic and epigenetic alterations of myeloproliferative disorders. <i>International Journal of Hematology</i> , 2013, 97, 183-197.	0.7	60
51	Telomerase activity in plant cells. <i>FEBS Letters</i> , 1996, 391, 307-309.	1.3	59
52	Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. <i>Blood Reviews</i> , 2005, 19, 1-13.	2.8	56
53	Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. <i>Blood</i> , 2019, 134, 199-210.	0.6	54
54	<i>JAK</i> Inhibitor in <i>CALR</i> -Mutant Myelofibrosis. <i>New England Journal of Medicine</i> , 2014, 370, 1168-1169.	13.9	52

#	ARTICLE	IF	CITATIONS
55	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. <i>Annals of Hematology</i> , 2015, 94, 1927-1928.	0.8	51
56	Germline RBBP6 mutations in familial myeloproliferative neoplasms. <i>Blood</i> , 2016, 127, 362-365.	0.6	49
57	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a <i>PCM1-JAK2</i> Fusion Gene. <i>Journal of Clinical Oncology</i> , 2013, 31, e269-e271.	0.8	47
58	Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2014, 89, 1107-1110.	2.0	47
59	The Triggering Receptor Expressed on Myeloid Cells 2 Inhibits Complement Component 1q Effector Mechanisms and Exerts Detrimental Effects during Pneumococcal Pneumonia. <i>PLoS Pathogens</i> , 2014, 10, e1004167.	2.1	46
60	A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family. <i>Haematologica</i> , 2008, 93, 706-714.	1.7	45
61	Overexpression of primary microRNA 221/222 in acute myeloid leukemia. <i>BMC Cancer</i> , 2013, 13, 364.	1.1	45
62	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with pegâ€prolineâ€interferon alphaâ€2b. <i>American Journal of Hematology</i> , 2015, 90, 288-294.	2.0	44
63	A time-resolved molecular map of the macrophage response to VSV infection. <i>Npj Systems Biology and Applications</i> , 2016, 2, 16027.	1.4	42
64	Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. <i>Blood</i> , 2016, 128, 1418-1423.	0.6	41
65	Identification of oncostatin M as a JAK2 V617Fâ€dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. <i>FASEB Journal</i> , 2012, 26, 894-906.	0.2	40
66	Identification of genomic aberrations associated with disease transformation by means of highâ€resolution SNP array analysis in patients with myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2011, 86, 974-979.	2.0	37
67	Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. <i>Leukemia</i> , 2022, 36, 1408-1411.	3.3	37
68	LNK mutations in familial myeloproliferative neoplasms. <i>Blood</i> , 2016, 128, 144-145.	0.6	36
69	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. <i>Leukemia</i> , 2020, 34, 510-521.	3.3	36
70	The telomeric sequence is directly attached to the HRS60 subtelomeric tandem repeat in tobacco chromosomes. <i>FEBS Letters</i> , 1995, 364, 33-35.	1.3	35
71	Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. <i>Blood Cancer Journal</i> , 2018, 8, 94.	2.8	34
72	The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. <i>Oncotarget</i> , 2016, 7, 51096-51106.	0.8	34

#	ARTICLE	IF	CITATIONS
73	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. <i>Blood</i> , 2018, 132, 4-4.	0.6	32
74	A novel germline <i>JAK2</i> mutation in familial myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2014, 89, 117-118.	2.0	31
75	A Comprehensive Analysis of the Dynamic Response to Aphidicolin-Mediated Replication Stress Uncovers Targets for ATM and ATMIN. <i>Cell Reports</i> , 2016, 15, 893-908.	2.9	29
76	CDK6 coordinates JAK2V617F mutant MPN via NF- $\kappa$ B and apoptotic networks. <i>Blood</i> , 2019, 133, 1677-1690.	0.6	29
77	Nested High-Resolution Melting Curve Analysis. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 263-270.	1.2	28
78	Congenital and inherited polycythemia. <i>Current Opinion in Pediatrics</i> , 2000, 12, 29-34.	1.0	27
79	Parallel genome-wide screens identify synthetic viable interactions between the BLM helicase complex and Fanconi anemia. <i>Nature Communications</i> , 2017, 8, 1238.	5.8	25
80	Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients. <i>Blood</i> , 2008, 112, 661-661.	0.6	23
81	Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. <i>American Journal of Hematology</i> , 2014, 89, 344-346.	2.0	20
82	Mutations in myeloproliferative neoplasms – their significance and clinical use. <i>Expert Review of Hematology</i> , 2017, 10, 961-973.	1.0	19
83	A polymorphism of the X-linked gene IDS increases the number of females informative for transcriptional clonality assays. , 2000, 63, 184-191.		18
84	A Downstream CpG Island Controls Transcript Initiation and Elongation and the Methylation State of the Imprinted Airn Macro ncRNA Promoter. <i>PLoS Genetics</i> , 2012, 8, e1002540.	1.5	18
85	Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. <i>British Journal of Haematology</i> , 2017, 179, 166-169.	1.2	18
86	Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. <i>International Journal of Hematology</i> , 2020, 111, 182-191.	0.7	18
87	Role of Germline Genetic Factors in MPN Pathogenesis. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1037-1051.	0.9	17
88	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6233.	5.8	17
89	Genetic Basis of MPN: Beyond JAK2-V617F. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 299-306.	1.2	16
90	6 Haematopoietic progenitors and signal transduction in polycythaemia vera and primary thrombocythaemia. <i>Best Practice and Research: Clinical Haematology</i> , 1998, 11, 803-818.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Germline genetic factors influence the outcome of interferon- $\alpha$ therapy in polycythemia vera. <i>Blood</i> , 2021, 137, 387-391.	0.6	14
92	Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. <i>Blood</i> , 2011, 118, 6468-6470.	0.6	13
93	Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia. <i>European Journal of Haematology</i> , 2014, 93, 103-111.	1.1	13
94	STAT5 is Expressed in CD34 <sup>+</sup> /CD38 <sup>+</sup> Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	1.7	12
95	Long-Term Efficacy and Safety of Ropeninterferon Alfa-2b in Patients with Polycythemia Vera â€” Final Phase I/II Peginvera Study Results. <i>Blood</i> , 2018, 132, 3030-3030.	0.6	12
96	Characterization of del20q in Peripheral Blood of MPD Patients Using Copy Number Analysis and High Resolution Oligonucleotide CGH Array. <i>Blood</i> , 2007, 110, 1530-1530.	0.6	12
97	DNA Curvature of the Tobacco GRS Repetitive Sequence Family and its Relation to Nucleosome Positioning. <i>Journal of Biomolecular Structure and Dynamics</i> , 1995, 12, 1103-1119.	2.0	11
98	Molecular basis and clonal evolution of myeloproliferative neoplasms. <i>Haematologica</i> , 2010, 95, 526-529.	1.7	11
99	Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms. <i>Current Cancer Drug Targets</i> , 2011, 11, 20-30.	0.8	11
100	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. <i>HemaSphere</i> , 2021, 5, e536.	1.2	11
101	Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis. <i>Blood</i> , 2014, 124, 157-157.	0.6	11
102	Acquired resistance to interferon alpha therapy associated with homozygous MPL $\Delta$ W515L mutation and chromosome 20q deletion in primary myelofibrosis. <i>European Journal of Haematology</i> , 2009, 82, 161-163.	1.1	10
103	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. <i>PLoS ONE</i> , 2013, 8, e77819.	1.1	9
104	Loss of Heterozygosity on Chromosome 9p24 Is the Most Frequent Chromosomal Aberration in Polycythemia Vera and Idiopathic Myelofibrosis.. <i>Blood</i> , 2004, 104, 2425-2425.	0.6	9
105	Molecular basis and clonal evolution of myeloproliferative neoplasms. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1889-1896.	1.4	8
106	Î¸ thalassemia major due to acquired uniparental disomy in a previously healthy adolescent. <i>Haematologica</i> , 2013, 98, e4-e6.	1.7	8
107	<sc>PD&L1</sc> overexpression correlates with <sc><i>JAK2</i>&V617F</sc> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 390-400.	2.0	8
108	Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed Patients with Essential Thrombocythemia: The ANAHYDRET-Study.. <i>Blood</i> , 2007, 110, 3547-3547.	0.6	7

#	ARTICLE	IF	CITATIONS
109	Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia.. Blood, 2009, 114, 435-435.	0.6	7
110	Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups. HemaSphere, 2020, 4, e485.	1.2	7
111	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2015, 56, 1938-1948.	0.6	6
112	Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor. Blood, 2021, 137, 1920-1931.	0.6	6
113	Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo. American Journal of Hematology, 2021, 96, 698-707.	2.0	6
114	Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Pegivera Study. Blood, 2013, 122, 4046-4046.	0.6	6
115	5-Arylidene-(4-hydroxyphenyl)aminothiazolones with selective inhibitory activity against some leukemia cell lines. Archiv Der Pharmazie, 2021, 354, 2000342.	2.1	5
116	Multimodality imaging beyond CLEM: Showcases of combined in-vivo preclinical imaging and ex-vivo microscopy to detect murine mural vascular lesions. Methods in Cell Biology, 2021, 162, 389-415.	0.5	5
117	Germline MPLW515R Mutation in a Family with Isolated Thrombocytosis. Blood, 2012, 120, 1764-1764.	0.6	5
118	AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV). Blood, 2012, 120, 175-175.	0.6	4
119	Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematological Oncology, 2018, 36, 740-748.	0.8	3
120	International external quality assurance of JAK2 V617F quantification. Annals of Hematology, 2019, 98, 1111-1118.	0.8	3
121	Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis. Cancers, 2020, 12, 2291.	1.7	3
122	Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms. Blood, 2018, 132, 3058-3058.	0.6	3
123	Overexpression of PD-L1 Correlates with JAK2-V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN. Blood, 2020, 136, 24-24.	0.6	3
124	Deletions of Chromosome 13q in Myeloproliferative Neoplasms: Mapping, Relation to the JAK2-V617F Mutation and Evaluation of Potential Tumor Suppressor Candidates. Blood, 2008, 112, 3724-3724.	0.6	3
125	The Role of Janus Kinases in Hematopoietic Malignancies. , 2012, , 239-258.		1
126	High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells. Blood Cancer Journal, 2021, 11, 137.	2.8	1



#	ARTICLE	IF	CITATIONS
127	Co-Expression of JAK2-V617F and Calr-del52 In Vivo Enhances Myeloproliferative Phenotype in Mice and Does Not Influence Competitive Fitness of Hematopoietic Stem Cells. <i>Blood</i> , 2020, 136, 20-20.	0.6	1
128	Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.. <i>Blood</i> , 2007, 110, 263-263.	0.6	1
129	Polymorphisms of NOS3 and FCGR2A Genes Contribute to Thrombotic Risk in Essential Thrombocythemia. <i>Blood</i> , 2007, 110, 1537-1537.	0.6	1
130	Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 4088-4088.	0.6	1
131	Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells. <i>Blood</i> , 2016, 128, 1959-1959.	0.6	1
132	Gene Expression Profiling Defines a Set of New Molecular Markers for Sporadic and Familial Myeloproliferative Disorders.. <i>Blood</i> , 2004, 104, 657-657.	0.6	0
133	Quantitative Analysis of Wild Type and V617F JAK-2 Expression in Neutrophils of Polycythemia Vera and Essential Thrombocythemia Patients at Diagnosis.. <i>Blood</i> , 2005, 106, 257-257.	0.6	0
134	Endothelial Dysfunction Is Independent of the JAK2 V617F Mutation in Polycythemia Vera.. <i>Blood</i> , 2006, 108, 4913-4913.	0.6	0
135	Lineage Distribution of JAK2 Exon12 Mutations and JAK2-V617F in Patients with Polycythemia Vera. <i>Blood</i> , 2007, 110, 1527-1527.	0.6	0
136	Chromosomal Instability Causes Genetic and Clonal Heterogeneity in Myeloproliferative Neoplasms and Is Not Restricted to JAK2-V617F Positive Cells. <i>Blood</i> , 2008, 112, 178-178.	0.6	0
137	Update on the Biology of Myeloproliferative Neoplasms. , 2012, , 3-10.		0
138	Phenotyping of Disease-Initiating CD34+/CD38 <sup>low</sup> Stem Cells in BCR-ABL1 <sup>+</sup> MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens. <i>Blood</i> , 2020, 136, 53-53.	0.6	0
139	Ifn $\gamma$ Attenuates the Disease Phenotype and Extends Survival in Mouse Models of MPN. <i>Blood</i> , 2020, 136, 53-53.	0.6	0